Diagnostics and treatment challenges of Ph-like acute lymphoblastic leukemia: a description of 3 clinical cases

Терапевтический архив

V G SAVCHENKO¹  E N PAROVICHNIKOVA¹  I V GALTSEVA¹  O A GAVRILINA¹  A E KRASILNIKOVA¹  Y O DAVYDOVA¹  V V TROITSKAYA¹  A B SUDARIKOV¹  K I ZARUBINA¹  G A BASKHAEVA¹  A N SOKOLOV¹  B V BIDERMAN¹  S N BONDARENKO² 

[1] National Research Center for Hematology;Pavlov First Saint Petersburg State Medical University;

关键词: ph-like acute lymphoblastic leukemia;    refractory;    tyrosine kinase inhibitors;    blinatumomab;    all-trans-retinoic acid;   

DOI  :  10.26442/terarkh2018907110-117

来源: DOAJ

【 摘 要 】

B-cell acute lymphoblastic leukemia (B-ALL) is a diverse group of malignant blood disorders both with regard to the biological properties of the tumor and to therapeutic approaches. Immunophenotyping, molecular genetic techniques, whole-genome sequencing characterize B-ALL as a very diverse group for sensitivity to chemotherapy and prognosis. We present three clinical cases of patients with B-ALL and expected good response to standard therapy, in whom standard protocol treatment failured: refractoriness, persistence of minimal residual disease (MRD), and progression (MRD increase). The remission in these patients was achieved after chemotherapy change to immunological targeted therapy. Nowadays a unified therapeutic approach to all primary patients of the B-ALL is considered generally outdated. Great efforts are carrying out to develop molecular genetic classifications. The molecular dissection of subtypes of B-ALL goes on, and new protocols for selective treatment with targeting are clearly outlined for each subtype of B-ALL.

【 授权许可】

Unknown